Surgery for esophageal cancer with or without immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and you were assigned female or male at birth (both sexes are allowed).
- Your esophageal cancer is squamous cell type and has not spread to distant organs on scans (no systemic metastasis).
- Your imaging shows no suspicious metastatic lymph nodes in the neck and no distant spread.
- Your doctors expect you can have surgery with complete tumor removal (R0 resection) and you’re physically able for treatment (ECOG 0–1).
- You have not had prior treatment for esophageal cancer, including chemotherapy, radiation, hormone therapy, or immunotherapy.
- Your blood counts, liver, kidneys, and clotting tests are within required ranges, and you must use effective birth control if you can become pregnant or have sperm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests different doses of radiation therapy combined with an immunotherapy drug called sintilimab for people with advanced esophageal cancer that hasn't spread far. The goal is to find the best dose to shrink tumors and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.